Cargando…
Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data
OBJECTIVES: To determine the prescription of guideline recommended drug therapy in patients with stable coronary heart disease (sCHD) prior to percutaneous coronary intervention (PCI) in Germany and to examine the role of patient characteristics and features of regional healthcare supply in a multil...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737102/ https://www.ncbi.nlm.nih.gov/pubmed/33318120 http://dx.doi.org/10.1136/bmjopen-2020-042886 |
_version_ | 1783622886535200768 |
---|---|
author | Frank-Tewaag, Julia Bleek, Julian Horenkamp-Sonntag, Dirk Marschall, Ursula Zeymer, Uwe Donner-Banzhoff, Norbert Sundmacher, Leonie |
author_facet | Frank-Tewaag, Julia Bleek, Julian Horenkamp-Sonntag, Dirk Marschall, Ursula Zeymer, Uwe Donner-Banzhoff, Norbert Sundmacher, Leonie |
author_sort | Frank-Tewaag, Julia |
collection | PubMed |
description | OBJECTIVES: To determine the prescription of guideline recommended drug therapy in patients with stable coronary heart disease (sCHD) prior to percutaneous coronary intervention (PCI) in Germany and to examine the role of patient characteristics and features of regional healthcare supply in a multilevel model. DESIGN: Secondary data analysis of factors associated with the prescription of guideline recommended drug therapy using a multilevel model to analyse regional-level effects, over and above the effects of patient-level demographic and health status. SETTING: Office-based prescriptions in the year prior to the invasive procedure. PARTICIPANTS: A linked nationwide dataset from Germany’s three largest statutory health insurance funds of all patients receiving PCI in the year 2016. MAIN OUTCOME MEASURES: Patients’ odds of receiving optimal medical therapy and symptom-oriented therapy within 1 year prior to PCI. RESULTS: 68.6% of patients received at least one lipid-lowering drug and one symptom-oriented therapy prior to PCI. 43.6% received at least two agents to control their symptoms. Patients who received treatment in accordance with the recommendations had a greater number of diagnosed risk factors, a more severe history of cardiac disease and used a higher volume of ambulatory office-based physician services. The prescriptions prevalence for the symptom-oriented therapies differed significantly between eastern and western Germany, with a higher prevalence in the eastern districts. CONCLUSIONS: Guidelines can only provide decision-making corridors, and the applicability of recommendations must always be assessed on a case by case basis. Nevertheless, our analysis indicates that the prevalence of prescriptions in routine practice is subject to substantial variation and that conservative therapy options are not fully exhausted prior to PCI. This suggests that there might be room for improvement in the care of patients with sCHD. |
format | Online Article Text |
id | pubmed-7737102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-77371022020-12-28 Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data Frank-Tewaag, Julia Bleek, Julian Horenkamp-Sonntag, Dirk Marschall, Ursula Zeymer, Uwe Donner-Banzhoff, Norbert Sundmacher, Leonie BMJ Open Health Services Research OBJECTIVES: To determine the prescription of guideline recommended drug therapy in patients with stable coronary heart disease (sCHD) prior to percutaneous coronary intervention (PCI) in Germany and to examine the role of patient characteristics and features of regional healthcare supply in a multilevel model. DESIGN: Secondary data analysis of factors associated with the prescription of guideline recommended drug therapy using a multilevel model to analyse regional-level effects, over and above the effects of patient-level demographic and health status. SETTING: Office-based prescriptions in the year prior to the invasive procedure. PARTICIPANTS: A linked nationwide dataset from Germany’s three largest statutory health insurance funds of all patients receiving PCI in the year 2016. MAIN OUTCOME MEASURES: Patients’ odds of receiving optimal medical therapy and symptom-oriented therapy within 1 year prior to PCI. RESULTS: 68.6% of patients received at least one lipid-lowering drug and one symptom-oriented therapy prior to PCI. 43.6% received at least two agents to control their symptoms. Patients who received treatment in accordance with the recommendations had a greater number of diagnosed risk factors, a more severe history of cardiac disease and used a higher volume of ambulatory office-based physician services. The prescriptions prevalence for the symptom-oriented therapies differed significantly between eastern and western Germany, with a higher prevalence in the eastern districts. CONCLUSIONS: Guidelines can only provide decision-making corridors, and the applicability of recommendations must always be assessed on a case by case basis. Nevertheless, our analysis indicates that the prevalence of prescriptions in routine practice is subject to substantial variation and that conservative therapy options are not fully exhausted prior to PCI. This suggests that there might be room for improvement in the care of patients with sCHD. BMJ Publishing Group 2020-12-13 /pmc/articles/PMC7737102/ /pubmed/33318120 http://dx.doi.org/10.1136/bmjopen-2020-042886 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Health Services Research Frank-Tewaag, Julia Bleek, Julian Horenkamp-Sonntag, Dirk Marschall, Ursula Zeymer, Uwe Donner-Banzhoff, Norbert Sundmacher, Leonie Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data |
title | Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data |
title_full | Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data |
title_fullStr | Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data |
title_full_unstemmed | Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data |
title_short | Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data |
title_sort | use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in germany: a multilevel analysis of nationwide routine data |
topic | Health Services Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737102/ https://www.ncbi.nlm.nih.gov/pubmed/33318120 http://dx.doi.org/10.1136/bmjopen-2020-042886 |
work_keys_str_mv | AT franktewaagjulia useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata AT bleekjulian useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata AT horenkampsonntagdirk useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata AT marschallursula useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata AT zeymeruwe useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata AT donnerbanzhoffnorbert useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata AT sundmacherleonie useofguidelinerecommendeddrugtherapyinpatientsundergoingpercutaneouscoronaryinterventionforstablecoronaryheartdiseaseingermanyamultilevelanalysisofnationwideroutinedata |